226 related articles for article (PubMed ID: 31160355)
41. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
[TBL] [Abstract][Full Text] [Related]
42. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
[TBL] [Abstract][Full Text] [Related]
43. Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations.
Xu M; Yan J; Hu B; Wu C; Gu H; Qi Z; Chen T; Yang W; Zheng Y; Dong H; Sheng W; Long J
Genes (Basel); 2022 Sep; 13(9):. PubMed ID: 36140756
[TBL] [Abstract][Full Text] [Related]
44. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Hackeng WM; Brosens LAA; Kim JY; O'Sullivan R; Sung YN; Liu TC; Cao D; Heayn M; Brosnan-Cashman J; An S; Morsink FHM; Heidsma CM; Valk GD; Vriens MR; Nieveen van Dijkum E; Offerhaus GJA; Dreijerink KMA; Zeh H; Zureikat AH; Hogg M; Lee K; Geller D; Marsh JW; Paniccia A; Ongchin M; Pingpank JF; Bahary N; Aijazi M; Brand R; Chennat J; Das R; Fasanella KE; Khalid A; McGrath K; Sarkaria S; Singh H; Slivka A; Nalesnik M; Han X; Nikiforova MN; Lawlor RT; Mafficini A; Rusev B; Corbo V; Luchini C; Bersani S; Pea A; Cingarlini S; Landoni L; Salvia R; Milione M; Milella M; Scarpa A; Hong SM; Heaphy CM; Singhi AD
Gut; 2022 May; 71(5):961-973. PubMed ID: 33849943
[TBL] [Abstract][Full Text] [Related]
45. Altered PTEN, ATRX, CHGA, CHGB, and TP53 expression are associated with aggressive VHL-associated pancreatic neuroendocrine tumors.
Weisbrod AB; Zhang L; Jain M; Barak S; Quezado MM; Kebebew E
Horm Cancer; 2013 Jun; 4(3):165-75. PubMed ID: 23361940
[TBL] [Abstract][Full Text] [Related]
46. Combined deletion of MEN1, ATRX and PTEN triggers development of high-grade pancreatic neuroendocrine tumors in mice.
Fuentes ME; Lu X; Flores NM; Hausmann S; Mazur PK
Sci Rep; 2024 Apr; 14(1):8510. PubMed ID: 38609433
[TBL] [Abstract][Full Text] [Related]
47. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
Fang JM; Shi J
Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
[TBL] [Abstract][Full Text] [Related]
48. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
49. The landscape of molecular alterations in pancreatic and small intestinal neuroendocrine tumours.
Scarpa A
Ann Endocrinol (Paris); 2019 Jun; 80(3):153-158. PubMed ID: 31072588
[TBL] [Abstract][Full Text] [Related]
50. DNA methylation reveals distinct cells of origin for pancreatic neuroendocrine carcinomas and pancreatic neuroendocrine tumors.
Simon T; Riemer P; Jarosch A; Detjen K; Di Domenico A; Bormann F; Menne A; Khouja S; Monjé N; Childs LH; Lenze D; Leser U; Rossner F; Morkel M; Blüthgen N; Pavel M; Horst D; Capper D; Marinoni I; Perren A; Mamlouk S; Sers C
Genome Med; 2022 Mar; 14(1):24. PubMed ID: 35227293
[TBL] [Abstract][Full Text] [Related]
51. Neuroendocrine Tumor of the Pancreas as a Manifestation of Cowden Syndrome: A Case Report.
Neychev V; Sadowski SM; Zhu J; Allgaeuer M; Kilian K; Meltzer P; Kebebew E
J Clin Endocrinol Metab; 2016 Feb; 101(2):353-8. PubMed ID: 26678657
[TBL] [Abstract][Full Text] [Related]
52. Impact of the tumor microenvironment in predicting postoperative hepatic recurrence of pancreatic neuroendocrine tumors.
Sato S; Tsuchikawa T; Nakamura T; Sato N; Tamoto E; Okamura K; Shichinohe T; Hirano S
Oncol Rep; 2014 Dec; 32(6):2753-9. PubMed ID: 25310565
[TBL] [Abstract][Full Text] [Related]
53. Gene fusions are frequent in ACTH-secreting neuroendocrine neoplasms of the pancreas, but not in their non-pancreatic counterparts.
Agaimy A; Kasajima A; Stoehr R; Haller F; Schubart C; Tögel L; Pfarr N; von Werder A; Pavel ME; Sessa F; Uccella S; La Rosa S; Klöppel G
Virchows Arch; 2023 Mar; 482(3):507-516. PubMed ID: 36690805
[TBL] [Abstract][Full Text] [Related]
54. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
[TBL] [Abstract][Full Text] [Related]
55. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
Shi C; Klimstra DS
Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
[TBL] [Abstract][Full Text] [Related]
56. Do Canine Pancreatic Neuroendocrine Neoplasms Resemble Human Pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation.
de Vries C; Konukiewitz B; Weichert W; Klöppel G; Aupperle-Lellbach H; Steiger K
J Comp Pathol; 2020 Nov; 181():73-85. PubMed ID: 33288156
[TBL] [Abstract][Full Text] [Related]
57. Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology: Well Differentiated Versus Poorly Differentiated.
Raj N; Valentino E; Capanu M; Tang LH; Basturk O; Untch BR; Allen PJ; Klimstra DS; Reidy-Lagunes D
Pancreas; 2017 Mar; 46(3):296-301. PubMed ID: 27759713
[TBL] [Abstract][Full Text] [Related]
58. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.
de Wilde RF; Edil BH; Hruban RH; Maitra A
Nat Rev Gastroenterol Hepatol; 2012 Feb; 9(4):199-208. PubMed ID: 22310917
[TBL] [Abstract][Full Text] [Related]
59. Neuroendocrine tumors of the pancreas: current concepts and controversies.
Reid MD; Balci S; Saka B; Adsay NV
Endocr Pathol; 2014 Mar; 25(1):65-79. PubMed ID: 24430597
[TBL] [Abstract][Full Text] [Related]
60. Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms.
Sigel CS; Guo H; Sigel KM; Zhang M; Rekhtman N; Lin O; Klimstra DS; Jungbluth AA; Tang LK
Cancer Cytopathol; 2017 Mar; 125(3):188-196. PubMed ID: 28094897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
